Wolfgang Miesbach: CMA CAR-T Induces Immune Reset and Durable Remission in Refractory ITP – EHA 2026 Late-Breaking Update
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Jinhui Shu et al, adding։
“Looking ahead to EHA 2026 next week, I am particularly interested in an upcoming late-breaking presentation:
- BCMA CAR-T Cell Therapy Induces Comprehensive Immune Resetting and Durable Remission in Refractory Primary Immune Thrombocytopenia
Targeting plasma cells and pathogenic antibody production represents a promising mechanistic shift beyond traditional B-cell–directed approaches.
It will be exciting to see how these strategies translate into clinical responses and immune modulation.”
Title: BCMA CAR-T cell therapy induces comprehensive immune resetting and durable remission in refractory primary immune thrombocytopenia
Authors: Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Peiru Li, Hongjian Li, James Bussel, Yu Hu, Heng Mei

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice